Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 131

Showing 1-25 of 131 citing articles:

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 92
The role of biomarkers in personalized immunotherapy
K. Nathan Sankar, Jing Christine Ye, Zihai Li, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 70
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components
Peng Zhang, Yuting Wang, Qianru Miao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115569-115569
Open Access | Times Cited: 23
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 7
Open Access | Times Cited: 15
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer
Lijuan Chen, Pengju Wang, Carmela Di Gioia, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
Julien Ancel, Valérian Dormoy, Béatrice Nawrocki‐Raby, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Immunotherapy-related biomarkers: Confirmations and uncertainties
Martina Catalano, Luigi Francesco Iannone, Gabriella Nesi, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104135-104135
Open Access | Times Cited: 14
SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer
Yaping Zhang, Qun Zhang, Xingzhi Han, et al.
Translational Oncology (2023) Vol. 31, pp. 101654-101654
Open Access | Times Cited: 13
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
Chih‐Wei Chu, Tomislav Čaval, Frederico Alisson‐Silva, et al.
Life Science Alliance (2024) Vol. 7, Iss. 3, pp. e202302368-e202302368
Open Access | Times Cited: 5
Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer
Yung‐Hung Luo, Yi‐Ping Yang, Chian‐Shiu Chien, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 64-64
Open Access | Times Cited: 31
PD-1 inhibition in advanced myeloproliferative neoplasms
Gabriela S. Hobbs, Cansu Cimen Bozkus, Erin Moshier, et al.
Blood Advances (2021) Vol. 5, Iss. 23, pp. 5086-5097
Open Access | Times Cited: 28
Macrophage Differentiation and Polarization Regulate the Release of the Immune Checkpoint Protein V-Domain Ig Suppressor of T Cell Activation
Gaetan Aime Noubissi Nzeteu, Stephanie Schlichtner, Sulamith David, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives
Mohammad Sadegh Soltani‐Zangbar, Forough Parhizkar, Mojtaba Abdollahi, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 21
Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
Yanjun Ge, Yuchen Zhang, Kong‐Nan Zhao, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3055-3070
Open Access | Times Cited: 19
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
Jair Bar, Raya Leibowitz‐Amit, Niels Reinmuth, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Prognostic significance of soluble PD-L1 in prostate cancer
Margarita Zvirble, Žilvinas Survila, Paulius Bosas, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
The influence of HLA genetic variation on plasma protein expression
Chirag Krishna, Joshua Chiou, Saori Sakaue, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Plasma inflammatory and angiogenic protein profiling of patients with sickle cell disease
Lydian A. de Ligt, Aafke E. Gaartman, Kadère Konté, et al.
British Journal of Haematology (2025)
Open Access
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy
Shay Tzaban, Otto Stern, Elad Zisman, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
Vesna Ćeriman Krstić, Dragana J. Jovanović, Natalija Samardžić, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 1, pp. 45-45
Open Access
Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
Shams ElDoha Galal ElDin Zaiema, Heba Mohamed Saber Hafez, Diaa El-Din Moussa Sherif Abou El-Ela, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Liquid-Based Diagnostic Panels for Prostate Cancer: The Synergistic Role of Soluble PD-L1, PD-1, and mRNA Biomarkers
Margarita Žvirblė, Ieva Vaicekauskaitė, Žilvinas Survila, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 704-704
Open Access
Lymphocyte Inhibition Mechanisms and Immune Checkpoints in COVID-19: Insights into Prognostic Markers and Disease Severity
Martina Schniederova, Anna Bobcakova, Marián Grendár, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 189-189
Open Access
Page 1 - Next Page

Scroll to top